
Semaglutide found to have shocking benefit for liver disease patients in new study
Fox News
Breakthrough research shows semaglutide effectively reverses life-threatening liver disease MASH, demonstrating significant inflammation reduction in 62.9% of clinical trial participants.
"This is a major step forward in the field," said Arun Sanyal, M.D., director of the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, in a video from VCU. "It provides patients with additional choices when we think about treating fatty liver disease." "I've been working with GLP-1 treatments for 16 years and these results are hugely exciting." Khloe Quill is a lifestyle production assistant with Fox News Digital. She and the lifestyle team cover a range of story topics including food and drink, travel, and health.
MASH is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD), which was previously known as non-alcoholic fatty liver disease, according to WebMD.













